Recombinant human granulocyte colony-stimulating factor (G-CSF) combined conditioning regimen for allogeneic bone marrow transplantation (BMT) in standard-risk myeloid leukemia

Satoshi Takahashi, Yasuo Oshima, Shinichiro Okamoto, Kaichi Nishiwaki, Hitomi Nagayama, Tokiko Inoue, Arinobu Tojo, Kenzaburo Tani, Shigetaka Asano

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We previously suggested that using a combined conditioning regimen including rhG-CSF with allogeneic BMT in refractory AML and CML in blast crisis might reduce the rate of relapse and improve disease-free survival, without any major side effects. In this study, we used the same protocol for 10 AML patients in complete remission (CR) and 6 CML patients in the chronic phase (CP). We compared disease-free survival as well as toxic side effects of the regimen with 6 AML patients in CR and 6 CML patients in CP treated with chemoradiotherapy without G-CSF. The conditioning regimen consisted of TBI and high-dose AraC. RhG-CSF was infused continuously at a dose of 5 μg/kg/day, starting 24 hr before the initial dose of total body irradiation (TBI) until the end of AraC therapy. In all 28 cases, there were no early stage deaths due to regimen-related toxicity (RRT). None of the 10 AML cases treated with the G-CSF combined regime relapsed. In 6 AML cases treated conventionally without G-CSF, one patient died of infection and another relapsed. There were no relapses in either CML group. In the combined G-CSF group, one patient died of interstitial pneumonitis 48 days after BMT, while the rest of the CML cases are still alive. There were no relapses with rhG- CSF and no serious adverse effects in terms of RRT, acute graff vs. host disease (GVHD), or leukocyte recovery.

Original languageEnglish
Pages (from-to)303-308
Number of pages6
JournalAmerican Journal of Hematology
Volume57
Issue number4
DOIs
Publication statusPublished - 1998 Apr
Externally publishedYes

Fingerprint

Myeloid Leukemia
Homologous Transplantation
Granulocyte Colony-Stimulating Factor
Bone Marrow Transplantation
Whole-Body Irradiation
Recurrence
Disease-Free Survival
Blast Crisis
Poisons
Interstitial Lung Diseases
Chemoradiotherapy
Leukocytes
Infection

Keywords

  • Acute myelocytic leukemia (AML)
  • Allogeneic bone marrow transplantation (BMT)
  • Chronic myelogenous leukemia (CML)
  • Cytosine arabinoside
  • Granulocyte colony-stimulating factor (G-CSF)

ASJC Scopus subject areas

  • Hematology

Cite this

Recombinant human granulocyte colony-stimulating factor (G-CSF) combined conditioning regimen for allogeneic bone marrow transplantation (BMT) in standard-risk myeloid leukemia. / Takahashi, Satoshi; Oshima, Yasuo; Okamoto, Shinichiro; Nishiwaki, Kaichi; Nagayama, Hitomi; Inoue, Tokiko; Tojo, Arinobu; Tani, Kenzaburo; Asano, Shigetaka.

In: American Journal of Hematology, Vol. 57, No. 4, 04.1998, p. 303-308.

Research output: Contribution to journalArticle

Takahashi, Satoshi ; Oshima, Yasuo ; Okamoto, Shinichiro ; Nishiwaki, Kaichi ; Nagayama, Hitomi ; Inoue, Tokiko ; Tojo, Arinobu ; Tani, Kenzaburo ; Asano, Shigetaka. / Recombinant human granulocyte colony-stimulating factor (G-CSF) combined conditioning regimen for allogeneic bone marrow transplantation (BMT) in standard-risk myeloid leukemia. In: American Journal of Hematology. 1998 ; Vol. 57, No. 4. pp. 303-308.
@article{04f7e58f4fb44480872f9834e48cb052,
title = "Recombinant human granulocyte colony-stimulating factor (G-CSF) combined conditioning regimen for allogeneic bone marrow transplantation (BMT) in standard-risk myeloid leukemia",
abstract = "We previously suggested that using a combined conditioning regimen including rhG-CSF with allogeneic BMT in refractory AML and CML in blast crisis might reduce the rate of relapse and improve disease-free survival, without any major side effects. In this study, we used the same protocol for 10 AML patients in complete remission (CR) and 6 CML patients in the chronic phase (CP). We compared disease-free survival as well as toxic side effects of the regimen with 6 AML patients in CR and 6 CML patients in CP treated with chemoradiotherapy without G-CSF. The conditioning regimen consisted of TBI and high-dose AraC. RhG-CSF was infused continuously at a dose of 5 μg/kg/day, starting 24 hr before the initial dose of total body irradiation (TBI) until the end of AraC therapy. In all 28 cases, there were no early stage deaths due to regimen-related toxicity (RRT). None of the 10 AML cases treated with the G-CSF combined regime relapsed. In 6 AML cases treated conventionally without G-CSF, one patient died of infection and another relapsed. There were no relapses in either CML group. In the combined G-CSF group, one patient died of interstitial pneumonitis 48 days after BMT, while the rest of the CML cases are still alive. There were no relapses with rhG- CSF and no serious adverse effects in terms of RRT, acute graff vs. host disease (GVHD), or leukocyte recovery.",
keywords = "Acute myelocytic leukemia (AML), Allogeneic bone marrow transplantation (BMT), Chronic myelogenous leukemia (CML), Cytosine arabinoside, Granulocyte colony-stimulating factor (G-CSF)",
author = "Satoshi Takahashi and Yasuo Oshima and Shinichiro Okamoto and Kaichi Nishiwaki and Hitomi Nagayama and Tokiko Inoue and Arinobu Tojo and Kenzaburo Tani and Shigetaka Asano",
year = "1998",
month = "4",
doi = "10.1002/(SICI)1096-8652(199804)57:4<303::AID-AJH6>3.0.CO;2-Y",
language = "English",
volume = "57",
pages = "303--308",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Recombinant human granulocyte colony-stimulating factor (G-CSF) combined conditioning regimen for allogeneic bone marrow transplantation (BMT) in standard-risk myeloid leukemia

AU - Takahashi, Satoshi

AU - Oshima, Yasuo

AU - Okamoto, Shinichiro

AU - Nishiwaki, Kaichi

AU - Nagayama, Hitomi

AU - Inoue, Tokiko

AU - Tojo, Arinobu

AU - Tani, Kenzaburo

AU - Asano, Shigetaka

PY - 1998/4

Y1 - 1998/4

N2 - We previously suggested that using a combined conditioning regimen including rhG-CSF with allogeneic BMT in refractory AML and CML in blast crisis might reduce the rate of relapse and improve disease-free survival, without any major side effects. In this study, we used the same protocol for 10 AML patients in complete remission (CR) and 6 CML patients in the chronic phase (CP). We compared disease-free survival as well as toxic side effects of the regimen with 6 AML patients in CR and 6 CML patients in CP treated with chemoradiotherapy without G-CSF. The conditioning regimen consisted of TBI and high-dose AraC. RhG-CSF was infused continuously at a dose of 5 μg/kg/day, starting 24 hr before the initial dose of total body irradiation (TBI) until the end of AraC therapy. In all 28 cases, there were no early stage deaths due to regimen-related toxicity (RRT). None of the 10 AML cases treated with the G-CSF combined regime relapsed. In 6 AML cases treated conventionally without G-CSF, one patient died of infection and another relapsed. There were no relapses in either CML group. In the combined G-CSF group, one patient died of interstitial pneumonitis 48 days after BMT, while the rest of the CML cases are still alive. There were no relapses with rhG- CSF and no serious adverse effects in terms of RRT, acute graff vs. host disease (GVHD), or leukocyte recovery.

AB - We previously suggested that using a combined conditioning regimen including rhG-CSF with allogeneic BMT in refractory AML and CML in blast crisis might reduce the rate of relapse and improve disease-free survival, without any major side effects. In this study, we used the same protocol for 10 AML patients in complete remission (CR) and 6 CML patients in the chronic phase (CP). We compared disease-free survival as well as toxic side effects of the regimen with 6 AML patients in CR and 6 CML patients in CP treated with chemoradiotherapy without G-CSF. The conditioning regimen consisted of TBI and high-dose AraC. RhG-CSF was infused continuously at a dose of 5 μg/kg/day, starting 24 hr before the initial dose of total body irradiation (TBI) until the end of AraC therapy. In all 28 cases, there were no early stage deaths due to regimen-related toxicity (RRT). None of the 10 AML cases treated with the G-CSF combined regime relapsed. In 6 AML cases treated conventionally without G-CSF, one patient died of infection and another relapsed. There were no relapses in either CML group. In the combined G-CSF group, one patient died of interstitial pneumonitis 48 days after BMT, while the rest of the CML cases are still alive. There were no relapses with rhG- CSF and no serious adverse effects in terms of RRT, acute graff vs. host disease (GVHD), or leukocyte recovery.

KW - Acute myelocytic leukemia (AML)

KW - Allogeneic bone marrow transplantation (BMT)

KW - Chronic myelogenous leukemia (CML)

KW - Cytosine arabinoside

KW - Granulocyte colony-stimulating factor (G-CSF)

UR - http://www.scopus.com/inward/record.url?scp=0031919850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031919850&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-8652(199804)57:4<303::AID-AJH6>3.0.CO;2-Y

DO - 10.1002/(SICI)1096-8652(199804)57:4<303::AID-AJH6>3.0.CO;2-Y

M3 - Article

C2 - 9544974

AN - SCOPUS:0031919850

VL - 57

SP - 303

EP - 308

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -